Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial

by Janice M Mehnert, Isaac Brownell, Sandra P D'Angelo, Kent C Shih, Karl D Lewis, Gerald P Linette, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Gülseren Güzel, Paul T Nghiem
Published 2020-06-01

Correction: Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report

by Janice M Mehnert, Isaac Brownell, Sandra P D'Angelo, Kent C Shih, Karl D Lewis, Gerald P Linette, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Gülseren Güzel, Paul T Nghiem
Published 2020-06-01

Correction: A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

by Janice M Mehnert, Isaac Brownell, Sandra P D'Angelo, Kent C Shih, Karl D Lewis, Gerald P Linette, Sara Georges, Parantu Shah, Barbara Ellers-Lenz, Gülseren Güzel, Paul T Nghiem
Published 2020-06-01

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

by Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Céleste Lebbé, Michele Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Anja von Heydebreck, Meliessa Hennessy, Paul Nghiem
Published 2018-01-01